Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Nonrandomized, open label, single arm study of neoadjuvant weekly carboplatin plus paclitaxel, followed by doxorubicin and cyclophosphamide in patients with operable Triple Negative Breast Cancer (TNBC)

sentinel lymph node biopsy
cyclophosphamide
carcinoma
EGFR
gilbert's syndrome
  • 54 views
  • 23 Jan, 2021
  • 1 location
Low-dose Y90 Treatment Planning for HCC

The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve optimal therapeutic dosing.

ct scan
cancer
platelet count
investigational treatment
measurable disease
  • 0 views
  • 25 Jan, 2021
  • 3 locations
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

Primary Objective: To confirm the safety and feasibility of canakinumab and spartalizumab (PDR-001) administered using a standard dose / schedule in the neo-adjuvant setting in renal cell carcinoma Secondary Objectives: To assess the immune response to combination canakinumab and spartalizumab To assess anti-tumor activity as measured by pathologic downstaging

clear cell renal cell carcinoma
neutrophil count
nephrectomy
carcinoma
  • 1 views
  • 29 Jan, 2021
Prostate Cancer - Patient Empowerment Program

Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option. Radical prostatectomy and/or radiation therapy are common procedures that are effective in the treatment of prostate cancer. However, they typically incur both short- and long-term side effects (e.g. urinary …

prostatectomy
immunological adjuvant
  • 5 views
  • 04 Feb, 2021
  • 1 location
Calcium Channel Blockade in Primary Aldosteronism

Primary aldosteronism is a common cause of hypertension. Recent evidence suggests that many patients with bilateral idiopathic hyperaldosteronism harbor gain-of-function somatic mutations in zona glomerulosa calcium channels that results in aldosterone production. This finding raises the possibility that calcium channel antagonists may be a targeted therapy to reduce aldosterone production …

aldosterone
amlodipine
hypertension
renin
hyperaldosteronism
  • 0 views
  • 25 Jan, 2021
International Low Anterior Resection Score Evaluation

using the LARS score. Primary outcome measure: LARS score before surgery and 1 year after the surgery. Primary comparison: Between average LARS score before and after curative

  • 2 views
  • 23 Jan, 2021
  • 1 location
Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer

or older. Objectives The investigators aim to determine the value of G8 to predict 30-day postoperative comorbidity in an older HNCA population undergoing elective curative surgery. Moreover

  • 9 views
  • 29 Jan, 2021
  • 1 location
CPET and Outcome After Oesophagogastric Cancer Surgery

surgery. Patients undergoing neoadjuvant chemotherapy or chemoradiotherapies will also be included. Patients having a CPET and initially scheduled for curative surgery, but end up not having surgery due

  • 0 views
  • 26 Jan, 2021
  • 1 location
Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer

of gastric cancer, as staging modalities for advanced (T3-4) tumors after initial staging. The costs of the study population will be compared to retrospective data of patients who underwent curative

ct scan
adenocarcinoma
laparoscopy
gastric adenocarcinoma
gastroscopy
  • 3 views
  • 21 Jan, 2021
  • 1 location
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

Collect real world safety data on the use of sonidegib in adult patients with laBCC. Document major safety parameters such as on treatment deaths, adverse events (AEs)/ serious adverse events (SAEs) and discontinuation secondary to AEs.

sonidegib
sonidegib 200 mg
carcinoma
  • 2 views
  • 28 Jan, 2021
  • 35 locations